Hospital.Help

Dallas – The significant weight reduction that GLP-1 agonists achieve in obese patients can alleviate the symptoms of heart failure with preserved ejection fraction, which is one of the possible long-term consequences of obesity. After a benefit was shown for semaglutide last year, results of a randomized study on the combined GIP/GLP-1 agonist tirzepatide are now available. They were…